Related Experiment Video

Updated: Aug 24, 2025

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples
14:39

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples

Published on: April 21, 2014

17.4K

Costs and Healthcare Resource Utilization for Obstructive Hypertrophic Cardiomyopathy With Septal Reduction Therapy

Michael Butzner1, Martin S Maron, Phil Sarocco

  • 1Health Economics and Outcomes Research, 350 Oyster Point Blvd, South San Francisco, CA 94080 USA. mbutzner@cytokinetics.com.

The Journal of Invasive Cardiology
|October 26, 2022
PubMed

Insights

Septal reduction therapies (SRTs) for obstructive hypertrophic cardiomyopathy (oHCM) significantly increase healthcare costs, primarily due to inpatient hospitalizations and surgical expenses. Both surgical septal myectomy (SM) and alcohol septal ablation (ASA) lead to higher economic burdens for patients.

Area of Science:

  • Cardiology
  • Health Economics
  • Medical Interventions

Background:

  • Obstructive hypertrophic cardiomyopathy (oHCM) often necessitates invasive septal reduction therapies (SRTs) for severe symptoms.
  • Surgical septal myectomy (SM) and alcohol septal ablation (ASA) are the primary SRT options.
  • Quantifying healthcare resource utilization (HCRU) and costs associated with these procedures is crucial.

Purpose of the Study:

  • To compare all-cause and oHCM-related HCRU and associated costs for patients undergoing SM versus ASA.
  • To analyze healthcare utilization and economic burden post-SRT.

Main Methods:

  • Retrospective analysis of medical and pharmacy claims from 2012-2020.
  • Comparison of HCRU and costs for 119 adults with oHCM undergoing SM (n=95) or ASA (n=24).
  • Analysis of baseline and follow-up periods post-procedure.

Main Results:

  • SM procedures involved longer inpatient stays (8.3 days) than ASA (6.0 days).
  • Post-procedure, SM patients had higher medication usage (98%) and increased outpatient visits compared to ASA patients.
  • Total mean HCM-related costs escalated significantly post-procedure for both groups, driven by inpatient and surgical expenses.

Conclusions:

  • SRT for oHCM leads to substantial increases in healthcare costs, particularly from inpatient stays and surgical fees.
  • Patients with oHCM undergoing SRT face a significant economic burden.
  • These findings are relevant for commercially insured and Medicare Advantage populations.
Abstract

Keywords:
cost-of-illnesseconomic burdenalcohol septal ablationhypertrophic cardiomyopathyseptal reduction therapyseptal myectomy

More Related Videos

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.5K
Echocardiographic Evaluation of Atrial Communications before Transcatheter Closure07:41

Echocardiographic Evaluation of Atrial Communications before Transcatheter Closure

Published on: February 8, 2022

3.8K

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
37
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
27
Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
22
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
20
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
19
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
16